Chapman, P.b., Hauschild, A., Robert, C., Larkin, J., Haanen, J., Ribas, A., et al. (2012). Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma. JOURNAL OF CLINICAL ONCOLOGY, 30(15 Supplement), 8502-8502 [10.1200/jco.2012.30.15_suppl.8502].

Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma

Maio M;
2012-01-01

2012
Chapman, P.b., Hauschild, A., Robert, C., Larkin, J., Haanen, J., Ribas, A., et al. (2012). Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma. JOURNAL OF CLINICAL ONCOLOGY, 30(15 Supplement), 8502-8502 [10.1200/jco.2012.30.15_suppl.8502].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1081132